Real-time financial, economic, and global news with market-focused context and analysis.
Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.
Adaptive Biotechnologies director Michelle Renee Griffin reported the sale of 15,394 shares on March 11, 2026, in a Form 4 filing with the SEC. The shares were sold at a weighted-average price of $13.91 for a total of $214,130. The transaction occurred as the stock traded at $13.17, a level InvestingPro considers above Fair Value. The company also …
Adaptive Biotechnologies Chief Financial Officer Kyle Piskel sold 18,672 shares on March 11, 2026, at $13.17 per share, generating $245,910. The sale was a mandated "sell to cover" to meet tax withholding tied to restricted stock unit vesting. The company’s stock has shown sharp short-term weakness despite a sizable 12-month gain, and InvestingPro …
Dianthus Therapeutics CEO Marino Garcia sold 122,918 shares on March 12, 2026, for roughly $10 million under a pre-arranged 10b5-1 plan and exercised options to acquire the same number of shares at $6.70 per share. The transactions coincide with a string of large equity raises and favorable interim data from the company’s Phase 3 CAPTIVATE trial, e…
Susan Bobulsky, Adaptive Biotechnologies' Chief Commercial Officer for MRD, sold 41,338 shares on March 11, 2026, at $13.17 per share for $544,421 to cover tax withholding on vested RSUs. The transaction follows a week of stock weakness and comes after the company reported stronger-than-expected fourth-quarter 2025 results and received several anal…
Adaptive Biotechnologies Chief Commercial Officer Sharon Benzeno sold 63,103 shares on March 11, 2026, for $13.17 per share, totaling $831,066. The sale was executed to meet tax withholding obligations tied to vesting restricted stock units under the company’s equity incentive plans. The transaction occurs after a recent 11% slide in the stock over…
Director Neil Mehta filed purchases of 7,350,104 Coupang Class A shares valued at $136.5 million in three transactions reported on a Form 4 with the SEC. The buys took place March 11-13, 2026, and follow a roughly 43% decline in the stock over the prior six months. The company reported Q4 2025 results that missed revenue and EPS expectations and dr…
Adaptive Biotechnologies executive Francis Lo sold 30,593 shares on March 11, 2026, for $430,749 under a Rule 10b5-1 plan. The transaction leaves Lo with 291,374 directly held shares and 2,500 indirectly held through a spouse. The stock has shown short-term weakness but strong one-year gains, while the company reported Q4 2025 results that beat est…
A man shot and killed by Dallas police this week had served on the security detail for U.S. Representative Jasmine Crockett, according to a report from CBS News Texas citing unnamed sources. Publicly identified as Mike King, the individual allegedly ran an online service placing off-duty officers in private jobs, used aliases, and faced accusations…
Adaptive Biotechnologies Corp's Chief Scientific Officer, Harlan S. Robins, sold 470,266 shares of company stock on March 11, 2026, for roughly $6.19 million. The two transactions were executed at $13.17 per share and were mandated by the company to satisfy tax withholding tied to vested restricted stock units and performance share units. The stock…
Nias James, chief accounting officer at nLIGHT, sold 1,808 shares on March 12, 2026, for a total of $116,471 under a pre-established Rule 10b5-1 plan. The disposition took place while the stock traded close to its 52-week peak following a year of substantial gains. Recent quarterly results and analyst price-target increases have highlighted the com…
Adaptive Biotechnologies Chief Executive Officer and Chairman Chad M. Robins completed two mandated sales of company shares on March 11, 2026, totaling 470,167 shares at $13.17 each, equal to roughly $6.19 million. The filings disclose the sales were to satisfy tax withholding obligations from vested restricted stock and performance share units and…
nLIGHT, Inc. director Raymond A. Link sold 25,404 shares of common stock between March 11 and March 13, 2026, for roughly $1.6 million under a Rule 10b5-1 plan adopted in December 2025. The transactions occurred while the stock traded close to its 52-week high following substantial year-over-year gains and better-than-expected fourth-quarter result…
Simrat Randhawa, Executive Vice President and Head of R&D at Dianthus Therapeutics, sold 33,830 shares for $2,756,468 and exercised options to acquire the same number of shares on March 12, 2026. The activity took place as the company completed a major public offering that raised about $719 million and after several analyst firms raised price targe…
Edward Carr, Chief Accounting Officer of Dianthus Therapeutics, sold 43,682 shares of the company’s common stock on March 12, 2026, generating about $3.56 million. On the same day he exercised options to acquire an equal number of shares at exercise prices between $17.88 and $22.07. The transactions take place as Dianthus stock has climbed sharply …
Symbotic Inc. director Saintil Merline filed a Form 4 showing two planned sales on March 11, 2026 that disposed of 3,414 shares of Class A common stock for about $173,483. The transactions occurred under a pre-arranged trading plan. The insider sale comes as the stock trades below the sale prices while the company reports mixed quarterly results an…
Crexendo Chief Strategy Officer Anand Buch sold 88,000 shares across two transactions on March 11 and March 13, 2026, according to a Form 4 filing, generating $579,200. The company reported fourth-quarter 2025 earnings that beat EPS expectations while revenue fell marginally short of estimates, and announced an acquisition of ESI that prompted Need…
Alpha Metallurgical Resources director Kenneth S. Courtis bought 10,000 shares on March 11, 2026, spending $1.8 million at prices between $185.28 and $187.87. The insider purchases come as the company reported a disappointing Q4 2025 with EPS and revenue misses, and as analysts kept Hold ratings while trimming price targets.
Kurt L. Kalbfleisch, CEO and CFO of Sphere 3D Corp (NASDAQ: ANY), sold 9,800 shares on March 13, 2026 for $1.59 per share, netting $15,582. The sale came one day after he exercised restricted stock units to acquire 18,358 shares. The company has recently regained Nasdaq minimum bid-price compliance, approved corporate governance measures at a speci…
Tiah Norton Reppas, Chief Accounting Officer of Sphere 3D Corp (NASDAQ: ANY), sold 6,250 shares on March 12, 2026 for $1.61 per share, totaling $10,062. The transaction followed an exercise of restricted stock units the day before and comes as the company reports regained Nasdaq minimum bid price compliance, a 1-for-10 reverse stock split, and shar…
Apogee Therapeutics CEO Michael Thomas Henderson sold 19,990 shares of company stock on March 11, 2026, under a Rule 10b5-1 plan adopted in August 2025. The trades, executed at prices between $74.29 and $75.86, reduced Henderson's direct holdings to 1,152,987 shares. The sale occurs amid strong share gains over the past year and a mix of analyst re…
Texas Roadhouse Chief Technology Officer Hernan E. Mujica sold 5,000 shares on March 13, 2026, for roughly $850,000. The transaction comes after the company reported fourth-quarter 2025 earnings that missed expectations, prompting mixed analyst revisions driven by beef inflation, weather disruptions and labor inefficiencies.
Meta is planning substantial workforce reductions that could affect 20% or more of its employees as the company seeks to offset heavy AI infrastructure spending and capture efficiency gains from AI-assisted work. Executives have signaled senior leaders to prepare for reductions, though no date or final headcount has been set. The moves would mark t…
Fox Corporation Executive Chair and CEO Lachlan Murdoch executed a series of stock sales of Class A Common Stock between March 11 and March 13, 2026, totaling approximately $65.4 million. The transactions, disclosed on a Form 4, include multiple block sales, an exchange with the LKM Family Trust, and option exercises. The activity occurred while Fo…
John Nallen, President and Chief Operating Officer of Fox Corporation, disposed of $26.5 million in Class A Common Stock across multiple trades on March 11 and 12, 2026, while simultaneously exercising options to acquire 459,115 shares. The sales were carried out under a pre-arranged Rule 10b5-1 trading plan adopted December 2, 2025. Fox reported a…
Sarepta Therapeutics director Stephen Mayo sold 7,239 shares of common stock on March 12, 2026, at $17.02 per share for $123,207 to satisfy tax obligations arising from vested restricted stock units. The transaction leaves Mayo with 1,765 shares directly held. Sarepta shares were trading near $16.40, a decline of 84% from their 52-week high of $103…
